Abstract:Background: A vaccine against COVID-19 has been developed; however, COVID-19 transmission continues. Although there have been many studies of comorbidities that have important roles in COVID-19, some studies have reported contradictory results. Objective: This study was conducted using real-world data from COVID-19 patients in South Korea and aimed to investigate the impact of patient demographics and comorbidities on the infection rate and severity of COVID-19. Methods: Data were derived from a nationwide South Korean COVID-19 cohort study with propensity score (PS) matching. We included infected individuals who were COVID-19-positive between January 1, 2020, and May 30, 2020, and PS-matched uninfected controls. PS matching was performed to balance the baseline characteristics of each comorbidity and to adjust for potential confounders, such as age, sex, Charlson Comorbidity Index, medication, and other comorbidities, that were matched with binary variables. The outcomes were the confirmed comorbidities affecting the infection rate and severity of COVID-19. The endpoints were COVID-19 positivity and severe clinical outcomes of COVID-19 (such as tracheostomy, continuous renal replacement therapy, intensive care unit admission, ventilator use, cardiopulmonary resuscitation, and death). Results: The COVID-19 cohort with PS matching included 8070 individuals with positive COVID-19 test results and 8070 matched controls. The proportions of patients in the severe group were higher for individuals 60 years or older (severe clinical outcomes for those 60 years or older, 16.52%; severe clinical outcomes for those of other ages, 2.12%), those insured with Medicaid (Medicaid, 10.81%; other insurance, 5.61%), and those with disabilities (with disabilities, 18.26%; without disabilities, 5.07%). The COVID-19 infection rate was high for patients with pulmonary disease (odds ratio [OR] 1.88; 95% CI 1.70-2.03), dementia (OR 1.75; 95% CI 1.40-2.20), gastrointestinal disease (OR 1.74; 95% CI 1.62-1.88), stroke (OR 1.67; 95% CI 1.23-2.27), hepatobiliary disease (OR 1.31; 95% CI 1.19-1.44), diabetes mellitus (OR 1.28; 95% CI 1.16-1.43), and cardiovascular disease (OR 1.20; 95% CI 1.07-1.35). In contrast, it was lower for individuals with hyperlipidemia (OR 0.73; 95% CI 0.67-0.80), autoimmune disease (OR 0.73; 95% CI 0.60-0.89), and cancer (OR 0.73; 95% CI 0.62-0.86). The severity of COVID-19 was high for individuals with kidney disease (OR 5.59; 95% CI 2.48-12.63), hypertension (OR 2.92; 95% CI 1.91-4.47), dementia (OR 2.92; 95% CI 1.91-4.47), cancer (OR 1.84; 95% CI 1.15-2.94), pulmonary disease (OR 1.72; 95% CI 1.35-2.19), cardiovascular disease (OR 1.54; 95% CI 1.17-2.04), diabetes mellitus (OR 1.43; 95% CI 1.09-1.87), and psychotic disorders (OR 1.29; 95% CI 1.01-6.52). However, it was low for those with hyperlipidemia (OR 0.78; 95% CI 0.60-1.00). Conclusions: Upon PS matching considering the use of statins, it was concluded that people with hyperlipidemia could have lower infection rates and disease severity of COVID-19.

Journal of Pharmaceutical Negative Results ¦ Volume 13 ¦ Issue 4 ¦ 2022 1172 ANALYSIS OF COMORBID DISEASE RISK FACTORS ON COVID-19 PATIENTS TO MORTALITY RATES IN SORONG CITY

Association Between Socio-demographic and Clinical Factors and Health Outcomes among COVID-19 Patients in a Community Hospital in Alabama

Risk Factor Analysis of Death due to COVID-19 with Comorbid Condition in the Community of the Wetland Environment in Banjar District

The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data

Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China

COVID-19 Predictors of Morbidity and Mortality

Clinical Manifestations of COVID-19 Patients with Comorbid and Non-comorbid at Dr. Soetomo Hospital, Surabaya

Relationship between Underlying Diseases with Morbidity and Mortality in Patients with COVID-19

Comorbidities and their association with COVID-19 mortality in Mexico between January 2020 and August 2021

Hypertension the major predictor of mortality in COVID-19: A retrospective study

Effect of Comorbidities on the Infection Rate and Severity of COVID-19: Nationwide Cohort Study With Propensity Score Matching

Risk factors associated with fatal outcomes of novel coronavirus infection pneumonia (COVID-19): A systematic review and meta-analysis

Characteristics and comorbidity of confirmed COVID-19 death cases at the Arifin Achmad Hospital in Riau province from March 2020 to September 2021

Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis

Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients

More severe comorbidities, advanced age, and incomplete vaccination increase the risk of COVID-19 mortality

COVID19 MORTALITY CORRELATION WITH THE BLOOD AND CYTOKINE LEVELS PARAMETERS IN 2021

Age-Adjusted in-Hospital Mortality in Patients with COVID-19 Infection: Impact of the Presence of Multiple Comorbidities

Risk Factors associated with COVID-19 Patients in India: A Single Center Retrospective Cohort Study

FACTORS ASSOCIATED WITH MORTALITY AMONG HOSPITALIZED CORONA VIRUS DISEASE 2019 ADULT PATIENTS WITH CHRONIC NON-COMMUNICABLE DISEASES IN DIRE DAWA, EASTERN ETHIOPIA

Mortality Rate of COVID-19 With Comorbid Pneumonia in a Rural Area